I wonder which will happen first: discovery of effective small-molecule drugs in this class, or improvements of peptide manufacturing to the point that cheap generics become possible. There are only 7 years left on the semaglutide patent but its manufacturing is currently so complicated that I don't expect really cheap generics after patent expiration.